Eli Lilly and Company announced the launch of a head-to-head study to compare once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant) for the prevention of migraine.
The U.S. Food and Drug Administration approved Biohaven Pharmaceutical Holding Company Ltd.’s Nurtec ODT (rimegepant 75 mg) for the preventive treatment of migraine. Nurtec ODT is indicated for adult patients with episodic migraine, e.g. those who experience less than 15 headache days per month.
Biogen and Capsigen forged a strategic collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to become transformative gene therapies that treat underlying genetic causes of various central nervous system and neuromuscular disorders.
The U.S. Food and Drug Administration accepted AbbVie’s New Drug Application for atogepant, an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist for the preventive treatment of migraine in adults who meet criteria for episodic migraine.
The U.S. Food and Drug Administration accepted for review Impel NeuroPharma’s 5O5(b)(2) New Drug Application (NDA) for INP104 for the acute treatment of migraine headaches with or without aura in adults.
BioSpace reviewed the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years.
Axsome Therapeutics reported positive data from the long-term, open-label Phase III MOVEMENT trial of AXS-07 for the treatment of acute migraine.
Novartis is acquiring Cambridge, Massachusetts-based neuroscience company Cadent Therapeutics for a $210 million upfront payment and potentially $560 million in milestone payments.
Syneos Health announced an agreement to acquire Synteract, a full-service contract research organization (CRO) focused on the biopharmaceutical industry.
Cerevel Therapeutics began trading on the Nasdaq.